Canopy Growth (CGC) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Canopy Growth (CGC) over the past year, gaining 28.0% versus a loss of 44.7%. Over five years, XERS leads with a +424.0% price change compared with -99.4% for CGC. Xeris Biopharma is the larger company by market cap ($1.91 billion vs $371.6 million), about 5.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | XERS |
|---|---|---|
| Share price | $0.8271 | $10.48 |
| Market cap | $371.62M | $1.91B |
| 1-day change | -2.33% | +2.85% |
| YTD return | -25.72% | +33.50% |
| 1-year return | -44.65% | +27.96% |
| 5-year return | -99.37% | +424.00% |
| Forward P/E | — | 28.32 |
| EPS (TTM) | $-0.45 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $2.38 | $11.33 |
| 52-week low | $0.81 | $5.25 |
| Distance from 52-week high | -65.25% | -7.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +45.09% | +22.71% |
| Average volume | 2.77M | 2.17M |
| Shares outstanding | 423.04M | 182.32M |
| Employees | 1,128 | 435 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Xeris Biopharma is about 5.1 times larger than Canopy Growth by market value ($1.91B vs $371.62M).
- XERS has outperformed CGC by 72.6 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Health Care · Medicinal Chemicals and Botanical Products · 1,128 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
CGC vs XERS FAQ
Which is bigger, Canopy Growth or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $371.62M for Canopy Growth (CGC).
Which stock has performed better over the past year, CGC or XERS?
XERS returned +27.96% over the past 12 months, compared with -44.65% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Xeris Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Canopy Growth and Biotechnology: Pharmaceutical Preparations for Xeris Biopharma.